Zepbound vs. Wegovy: Which GLP-1 Agonist Is Right for You?

The landscape of weight management has shifted dramatically with the introduction of powerful injectable medications. If you have been researching medical weight loss options, you have likely encountered two major competitors: Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. While both drugs effectively target appetite and blood sugar regulation, they utilize different biological mechanisms to achieve results. Understanding these distinct differences is essential for choosing the treatment path that aligns best with your health goals and budget.

Understanding the Active Ingredients

To compare these medications fairly, you must look at the active ingredients inside the injection pens. While they are often grouped together as “GLP-1 drugs,” Zepbound actually belongs to a newer class of medication.

Wegovy (Semaglutide)

Wegovy contains semaglutide. This is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics a hormone your body naturally produces in the gut after you eat. This hormone signals your brain that you are full and slows down how quickly your stomach empties. By keeping food in your stomach longer and suppressing appetite signals in the brain, Wegovy helps you eat fewer calories.

Zepbound (Tirzepatide)

Zepbound contains tirzepatide. This is the first medication in a class called dual GIP/GLP-1 receptor agonists. It mimics the GLP-1 hormone just like Wegovy, but it also mimics a second hormone called glucose-dependent insulinotropic polypeptide (GIP).

Researchers believe GIP works synergistically with GLP-1. While GLP-1 focuses heavily on satiety, GIP may enhance how the body breaks down sugar and fat while further reducing appetite. This dual-action approach is why tirzepatide is often referred to as a “twincretin.”

Comparing Weight Loss Efficacy

Clinical trials suggest that Zepbound may offer a slight edge regarding total percentage of body weight lost, likely due to its dual-hormone mechanism. However, both drugs provide results significantly superior to diet and exercise alone.

The Data on Wegovy

The approval of Wegovy was largely based on the STEP clinical trials. In the STEP 1 trial, participants without diabetes who took the maximum 2.4 mg dose of semaglutide lost an average of 14.9% of their body weight over 68 weeks. This was a massive leap forward compared to older weight loss medications which typically offered 5% to 10% loss.

The Data on Zepbound

Zepbound’s approval followed the SURMOUNT clinical trials. In the SURMOUNT-1 study, participants taking the highest dose (15 mg) of tirzepatide lost an average of 20.9% of their body weight over 72 weeks.

While head-to-head trials are still ongoing or being analyzed, current data indicates that the addition of the GIP receptor agonist allows Zepbound to produce greater weight reduction for many patients.

Pricing and Insurance Coverage

Cost is often the deciding factor for patients. These medications are expensive, and insurance coverage varies wildly depending on your specific plan and employer.

Wegovy Costs:

• List Price: Approximately $1,349 per month.
• Manufacturer Support: Novo Nordisk offers a “WeGoTogether” savings card. If you have commercial insurance that covers the drug, you may pay as little as $0 to $25 per month. If your insurance does not cover the drug, the savings are limited, typically knocking about $500 off the retail price.

Zepbound Costs:

• List Price: Approximately $1,060 per month.
• Manufacturer Support: Eli Lilly has positioned Zepbound with a lower list price to be more competitive. Their savings card program allows those with commercial insurance coverage to pay as little as $25 per month. Crucially, for those with commercial insurance that does not cover Zepbound, the card can reduce the price to approximately $550 per month, which is significantly more affordable than the out-of-pocket cost for Wegovy.

Dosage and Administration

Both medications are subcutaneous injections administered once weekly. You inject them into the abdomen, thigh, or upper arm.

Wegovy Dosing Schedule: You start at a low dose of 0.25 mg and increase every four weeks until you reach the maintenance dose of 2.4 mg. This slow titration helps mitigate side effects.

Zepbound Dosing Schedule: Zepbound follows a similar escalation. You begin at 2.5 mg and increase by 2.5 mg increments every four weeks. The maximum maintenance dose is 15 mg, though some patients maintain weight loss effectively on 5 mg, 10 mg, or 12.5 mg doses.

Side Effect Profiles

Because both drugs influence the gut and digestion, their side effect profiles are remarkably similar. Most side effects are gastrointestinal and tend to occur most intensely when you first start the medication or when you increase the dose.

Common side effects for both include:

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Abdominal pain
• Fatigue

Some studies suggest that despite the higher efficacy of Zepbound, the side effect rates are comparable to Wegovy. This is because the GIP hormone may actually provide a slight anti-nausea effect that counteracts the GLP-1 intensity, though individual experiences vary greatly.

Severe but rare risks for both medications include pancreatitis, gallbladder problems, and potential thyroid C-cell tumors (observed in rodent studies).

Supply Chain and Availability

A practical consideration for choosing between these two is simply which one you can find at your pharmacy. Since 2023, both Novo Nordisk and Eli Lilly have struggled to meet the skyrocketing demand.

The FDA maintains a drug shortage database that tracks availability. At various times, starting doses for Wegovy (0.25 mg, 0.5 mg) have been extremely difficult to locate. Zepbound has also faced intermittent supply constraints, particularly for the 10 mg and 12.5 mg doses. Before starting either regimen, it is wise to call local pharmacies to check their current stock levels.

Who Is Eligible?

The FDA criteria for prescribing these medications are identical. You generally qualify if you meet one of the following standards:

1. Obesity: A Body Mass Index (BMI) of 30 or higher.
2. Overweight: A BMI of 27 or higher, accompanied by at least one weight-related condition such as hypertension (high blood pressure), type 2 diabetes, or high cholesterol.

Doctors have the discretion to prescribe these off-label, but insurance will rarely cover the cost without meeting these strict criteria.

Frequently Asked Questions

Can I switch from Wegovy to Zepbound? Yes, many patients switch. This often happens if a patient hits a weight loss plateau on Wegovy or experiences intolerable side effects. Because Zepbound targets an additional receptor, it may restart weight loss for those who have stalled on semaglutide. You should consult your doctor regarding the correct starting dose when switching.

Do these drugs burn fat directly? No. These drugs do not “melt” fat. They regulate appetite and blood sugar. They make it easier for you to remain in a calorie deficit, which causes your body to burn stored fat for energy.

Will I regain the weight if I stop taking Zepbound or Wegovy? Clinical data suggests that weight regain is likely if the medication is discontinued. Obesity is increasingly viewed by the medical community as a chronic condition requiring long-term management, similar to how high blood pressure is treated. Most patients will need to stay on a maintenance dose to keep the weight off.

Is Zepbound the same thing as Mounjaro? Yes. Mounjaro and Zepbound are the exact same drug (tirzepatide) manufactured by Eli Lilly. Mounjaro is FDA-approved for type 2 diabetes, while Zepbound is FDA-approved for weight management.

Is Wegovy the same thing as Ozempic? Yes. Ozempic and Wegovy are both semaglutide manufactured by Novo Nordisk. Ozempic is approved for type 2 diabetes (and usually tops out at a 2.0 mg dose), while Wegovy is approved for weight loss (and goes up to 2.4 mg).